Haleon plc (HLN)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Haleon plc (HLN) trades at $9.12 with AI Score 49/100 (Grade C). Haleon plc is a global consumer healthcare company focused on over-the-counter products. Market cap: $40.48B, Sector: Healthcare.
Last analyzed: Mar 15, 2026Analyst Coverage for HLN: HLN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HLN against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
HLN: 2/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
Haleon plc (HLN) Healthcare & Pipeline Overview
Haleon plc is a global leader in consumer healthcare, offering a diverse portfolio of over-the-counter products across various therapeutic categories. With a strong focus on oral health, pain relief, and respiratory health, Haleon leverages its established brands and extensive distribution network to maintain a competitive edge in the consumer healthcare market.
What Is the Investment Thesis for HLN?
Haleon presents a compelling investment case based on its strong market position in the consumer healthcare sector and its portfolio of well-known brands. The company's focus on over-the-counter products provides a degree of resilience to economic cycles. A key value driver is Haleon's ability to innovate and launch new products that meet evolving consumer needs. Growth catalysts include expanding into emerging markets and increasing penetration in existing markets through targeted marketing campaigns. With a profit margin of 13.8% and a gross margin of 61.8%, Haleon demonstrates solid profitability. Potential risks include increasing competition from generic brands and changes in consumer preferences.
Based on FMP financials and quantitative analysis
HLN Key Highlights
- Haleon's market capitalization stands at $44.67 billion, reflecting its significant presence in the consumer healthcare market.
- The company's P/E ratio is 22.30, indicating investor expectations for future earnings growth.
- Haleon boasts a strong gross margin of 61.8%, showcasing its ability to manage production costs and maintain pricing power.
- With a profit margin of 13.8%, Haleon demonstrates efficient operations and effective cost management.
- Haleon offers a dividend yield of 1.50%, providing investors with a steady stream of income.
Who Are HLN's Competitors?
HLN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| A Agilent Technologies, Inc. | $135.21 | +1.90% | $38.19B | 52 |
| ALC Alcon Inc. | $67.75 | +2.49% | $33.02B | 51 |
| BDX Becton, Dickinson and Company | $147.12 | +0.94% | $53.30B | 51 |
| CAH Cardinal Health, Inc. | $195.15 | +0.03% | $45.71B | 42 |
| HUM Humana Inc. | $363.17 | +0.25% | $43.60B | 50 |
| ALVO Alvotech | $4.16 | -1.89% | 2B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HLN's Key Strengths?
- Strong brand portfolio with leading positions in key categories.
- Global distribution network and market presence.
- Consistent investment in research and development.
- Experienced management team.
What Are HLN's Weaknesses?
- Dependence on key brands and therapeutic areas.
- Exposure to currency fluctuations.
- Potential for product liability claims.
- Reliance on third-party manufacturers for some products.
What Could Drive HLN Stock Higher?
- Continued investment in research and development to drive innovation and new product launches.
- Expansion into emerging markets with high growth potential.
- Strategic acquisitions to expand product portfolio and geographic reach.
- Potential regulatory approvals for new products in key markets (timeline varies by product and region).
- Launch of new marketing campaigns to increase brand awareness and drive sales (planned for Q3 2026).
What Are the Key Risks for HLN?
- Increasing competition from generic brands and private label products.
- Changes in consumer preferences and purchasing habits.
- Regulatory changes and healthcare reforms.
- Economic downturns and reduced consumer spending.
- Exposure to currency fluctuations.
What Are the Growth Opportunities for HLN?
- Expanding into emerging markets represents a significant growth opportunity for Haleon. These markets, particularly in Asia and Latin America, are experiencing rapid economic growth and increasing demand for consumer healthcare products. By tailoring its product offerings to local preferences and leveraging its distribution network, Haleon can capture a larger share of these markets. The market size for consumer healthcare in emerging markets is estimated to reach $200 billion by 2028.
- Innovation and new product development are crucial for driving organic growth. Haleon can invest in research and development to create new formulations, delivery systems, and product categories that address unmet consumer needs. This includes developing products that cater to specific demographics, such as seniors or children. The global market for innovative consumer healthcare products is projected to grow at a rate of 5% annually over the next five years.
- Increasing penetration in existing markets through targeted marketing campaigns is another key growth driver. Haleon can leverage its brand recognition and marketing expertise to reach new customers and increase sales in its core markets. This includes utilizing digital marketing channels, social media, and influencer marketing to engage with consumers. The market for digital marketing in the consumer healthcare sector is expected to reach $15 billion by 2027.
- Strategic acquisitions can help Haleon expand its product portfolio and geographic reach. By acquiring smaller companies with complementary products or technologies, Haleon can strengthen its competitive position and accelerate growth. This includes targeting companies with strong brands in niche markets or companies with innovative technologies in the consumer healthcare space. The market for mergers and acquisitions in the consumer healthcare sector is expected to remain active in the coming years.
- Focusing on sustainability and ethical sourcing can enhance Haleon's brand reputation and attract environmentally conscious consumers. By implementing sustainable manufacturing practices, reducing its environmental footprint, and sourcing ingredients ethically, Haleon can differentiate itself from competitors and build stronger relationships with its customers. The market for sustainable consumer healthcare products is projected to grow at a rate of 8% annually over the next five years.
What Opportunities Does HLN Have?
- Expanding into emerging markets with high growth potential.
- Developing new products and formulations to meet evolving consumer needs.
- Acquiring complementary businesses to expand product portfolio.
- Leveraging digital marketing and e-commerce channels to reach new customers.
What Threats Does HLN Face?
- Increasing competition from generic brands and private label products.
- Changes in consumer preferences and purchasing habits.
- Regulatory changes and healthcare reforms.
- Economic downturns and reduced consumer spending.
What Are HLN's Competitive Advantages?
- Strong brand recognition and loyalty for key products like Sensodyne and Panadol.
- Extensive global distribution network reaching a wide range of consumers.
- Significant investment in research and development to innovate and launch new products.
- Economies of scale in manufacturing and distribution.
What Does HLN Do?
Haleon plc, incorporated in 2021 and headquartered in Brentford, United Kingdom, is a global consumer healthcare company that researches, develops, manufactures, and sells a wide range of over-the-counter (OTC) products. Spun out to focus on consumer health, Haleon's origins lie in the consumer healthcare divisions of major pharmaceutical companies. The company's portfolio spans several therapeutic areas, including oral health (Sensodyne, Polident, parodontax), pain relief (Panadol, Voltaren, Advil), respiratory health (Otrivin, Theraflu), digestive health, and vitamins, minerals, and supplements (Centrum). Haleon distributes its products across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. Haleon's strategy focuses on driving organic growth through innovation, brand building, and geographic expansion, while also pursuing strategic acquisitions to strengthen its portfolio and market position. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022.
What Products and Services Does HLN Offer?
- Researches and develops over-the-counter (OTC) healthcare products.
- Manufactures a wide range of consumer healthcare products.
- Markets and sells its products across various geographic regions.
- Offers products in oral health, pain relief, and respiratory health.
- Provides vitamins, minerals, and supplements.
- Manages a portfolio of well-known brands like Panadol, Voltaren, and Sensodyne.
- Distributes products through retail channels and online platforms.
How Does HLN Make Money?
- Develops and manufactures branded consumer healthcare products.
- Sells products through retail channels, pharmacies, and online platforms.
- Generates revenue through product sales across various therapeutic categories.
- Invests in marketing and advertising to build brand awareness and drive sales.
What Industry Does HLN Operate In?
Haleon operates in the global consumer healthcare market, which is characterized by increasing demand for over-the-counter medications and health supplements. The market is driven by factors such as an aging population, rising healthcare costs, and growing consumer awareness of preventive healthcare. The competitive landscape includes major multinational corporations and smaller regional players. Haleon's strong brand portfolio and global distribution network position it well to compete effectively in this market. Key competitors include companies like Abbott Laboratories (A), which also has a significant presence in the consumer health space.
Who Are HLN's Key Customers?
- Individual consumers seeking over-the-counter healthcare solutions.
- Retail pharmacies and drugstores that stock and sell Haleon's products.
- Online retailers and e-commerce platforms.
- Hospitals and healthcare providers (for certain products).
HLN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests strong confidence in Haleon's growth trajectory, indicating that key stakeholders believe in the company's potential.
- Community sentiment has shifted positively, with discussions highlighting Haleon's innovative product pipeline and market expansion strategies.
- The company's commitment to sustainability resonates with consumers, enhancing brand loyalty and market perception.
- Positive reception of recent earnings reports reflects a growing belief in Haleon's ability to navigate market challenges effectively.
Bear Case
- Concerns over inflationary pressures impacting consumer spending could affect Haleon's revenue growth, leading to cautious sentiment among investors.
- Recent social media discussions reveal skepticism regarding the effectiveness of Haleon's marketing strategies compared to competitors.
- Insider selling activity has raised alarms, suggesting that some insiders may foresee potential challenges ahead for the company's performance.
- Market analysts have pointed to increased competition in the consumer health sector, which may dilute Haleon's market share and profitability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $2.78B | $485M | $0.11 |
| Q4 2024 | $2.76B | $231M | — |
Based on FMP financials and quantitative analysis
HLN Latest News
-
Haleon to Invest $233.1 Million in India Oral Care Expansion
MT Newswires · Jun 8, 2026
-
Haleon to Invest £175M in New India Oral Health Plant
benzinga · Jun 8, 2026
-
Haleon to Invest $233.5 Million in India Plant Amid Push Into Emerging Markets
The Wall Street Journal · Jun 8, 2026
-
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities
businesswire.com · Jun 8, 2026
HLN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HLN.
Price Targets
Wall Street price target analysis for HLN.
HLN MoonshotScore
What does this score mean?
The MoonshotScore rates HLN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Haleon to Invest $233.1 Million in India Oral Care Expansion
Haleon to Invest £175M in New India Oral Health Plant
Haleon to Invest $233.5 Million in India Plant Amid Push Into Emerging Markets
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities
Leadership: Brian James McNamara
CEO
Brian James McNamara serves as the Chief Executive Officer of Haleon. He has extensive experience in the consumer healthcare industry, having held various leadership positions at major multinational corporations. Prior to joining Haleon, McNamara served in leadership at GSK Consumer Healthcare. His career spans over two decades, with a focus on driving growth, innovation, and operational excellence. McNamara's background includes a strong track record of building and managing successful consumer brands.
Track Record: Since becoming CEO of Haleon, Brian James McNamara has focused on establishing the company as a leading independent consumer healthcare business. Key achievements include successfully separating Haleon from its parent company and implementing a strategic plan focused on organic growth, innovation, and geographic expansion. McNamara has also overseen the launch of several new products and initiatives aimed at strengthening Haleon's brand portfolio and market position.
Haleon plc ADR Information
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that trades on U.S. stock exchanges. For HLN, each ADR represents a specific number of ordinary shares of Haleon plc traded on its home market. This allows U.S. investors to invest in HLN without dealing with foreign exchanges.
- Home Market Ticker: London Stock Exchange (LSE), United Kingdom
HLN Healthcare Stock FAQ
What does Haleon plc do?
Haleon plc is a global consumer healthcare company focused on developing, manufacturing, and marketing a wide range of over-the-counter (OTC) products. Its portfolio includes well-known brands in oral health (Sensodyne, Polident), pain relief (Panadol, Voltaren), respiratory health (Otrivin, Theraflu), digestive health, and vitamins, minerals, and supplements (Centrum). Haleon's products are sold through retail channels, pharmacies, and online platforms in North America, Europe, Asia Pacific, Latin America, and other regions. The company focuses on providing consumers with accessible and reliable healthcare solutions for everyday needs.
What do analysts say about HLN stock?
Analyst consensus on HLN stock is Unknown, based on limited available data. Key valuation metrics such as the P/E ratio (22.30) and dividend yield (1.50%) provide some insight into investor expectations. Growth considerations include Haleon's ability to expand into emerging markets, innovate new products, and manage competition from generic brands. Analysts will likely monitor the company's financial performance, regulatory developments, and market trends to assess its long-term growth potential. Further analyst reports are needed to provide a comprehensive overview.
What are the main risks for HLN?
Haleon faces several risks, including increasing competition from generic brands and private label products, which could erode its market share and pricing power. Changes in consumer preferences and purchasing habits could also impact demand for its products. Regulatory changes and healthcare reforms could create uncertainty and increase compliance costs. Economic downturns and reduced consumer spending could negatively affect sales. Additionally, Haleon is exposed to currency fluctuations, which could impact its financial results.
How does Haleon plc navigate regulatory approval processes?
As a consumer healthcare company, Haleon must navigate complex regulatory approval processes in various countries to market its products. This involves complying with regulations set by agencies such as the FDA in the United States and the EMA in Europe. Haleon's regulatory strategy includes conducting clinical trials to demonstrate product safety and efficacy, preparing detailed regulatory submissions, and maintaining ongoing compliance with regulatory requirements. Any delays or failures in obtaining regulatory approvals could negatively impact Haleon's ability to launch new products and maintain its market position.
What revenue streams does Haleon plc have in healthcare?
Haleon's revenue streams are diversified across several product lines, therapeutic areas, and geographic markets. The company generates revenue from the sale of oral health products (Sensodyne, Polident), pain relief medications (Panadol, Voltaren, Advil), respiratory health treatments (Otrivin, Theraflu), digestive health products, and vitamins, minerals, and supplements (Centrum). Revenue is also generated from sales in North America, Europe, Asia Pacific, Latin America, and other regions. The specific breakdown of revenue by product line, therapeutic area, and geographic market is Unknown, but the diversification helps to mitigate risk and provide a stable revenue base.
What are the key factors to evaluate for HLN?
Haleon plc (HLN) holds an AI score of 49/100 (low). P/E: 29.4x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does HLN data refresh on this page?
HLN prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven HLN's recent stock price performance?
Haleon plc (HLN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong brand portfolio with leading positions in key categories. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Analyst consensus is based on limited data and may not be fully representative.